Management of a 66-Year-Old Woman with Recent Stent, Active GI Bleeding, and Creatinine 1.7
In this patient with recent coronary stent placement and active upper GI bleeding, immediately discontinue dual antiplatelet therapy (DAPT), start IV proton pump inhibitor, perform urgent upper endoscopy within 12 hours, and resume aspirin monotherapy (not DAPT) once hemostasis is achieved, given the competing catastrophic risks of stent thrombosis versus exsanguination. 1
Immediate Antiplatelet Management
The 2018 ESC guidelines provide direct case-based evidence for this exact scenario 1. When major GI bleeding occurs after stent placement:
- Stop both antiplatelet agents immediately during active hemodynamically significant bleeding
- The risk of continuing DAPT during active bleeding outweighs stent thrombosis risk in the acute phase
- However, interruption of antiplatelet therapy creates a prothrombotic state that must be minimized
Critical timing: Perform upper GI endoscopy within 12 hours of presentation. The ESC guidelines explicitly state that delayed endoscopy (>12 hours) increases stent thrombosis risk by prolonging the period without antiplatelet coverage 1.
Endoscopic Intervention Priority
This patient requires urgent endoscopy (<12 hours) with:
- IV proton pump inhibitor initiated immediately
- Aggressive volume resuscitation and transfusion to hemoglobin >8.5 g/dL
- Definitive endoscopic hemostasis (thermal therapy, clips, or injection)
The ESC case series demonstrates that the 39-hour delay between bleeding and endoscopy contributed to stent thrombosis 1. Every hour of delay increases thrombotic risk.
Antiplatelet Resumption Strategy
Once hemostasis is endoscopically confirmed:
- Resume aspirin monotherapy only (75-100 mg daily) 1
- Do NOT resume the P2Y12 inhibitor (clopidogrel/ticagrelor/prasugrel) initially
- Continue PPI indefinitely
Rationale: The 2018 ESC guidelines show that in patients with high bleeding risk post-stent, aspirin monotherapy provides acceptable ischemic protection while substantially reducing rebleeding risk 1. The case evidence demonstrates that attempting to maintain DAPT in active GI bleeding leads to either fatal bleeding or fatal stent thrombosis.
Renal Function Considerations (Creatinine 1.7)
With serum creatinine 1.7 mg/dL, estimated creatinine clearance is approximately 30-45 mL/min in a 66-year-old woman 2, 3:
Medication adjustments required:
- Aspirin: No dose adjustment needed 4
- Clopidogrel (if restarted later): No dose adjustment 4
- Ticagrelor (if restarted later): No dose adjustment 4
- ACE inhibitors: Continue but monitor creatinine closely; up to 30% increase is acceptable 5
- Avoid NSAIDs completely 6
The ACC/AHA guidelines mandate creatinine clearance estimation in all ACS patients to guide drug dosing 7, 2. This patient's renal impairment increases bleeding risk substantially and supports the decision for aspirin monotherapy over DAPT.
Management of Hypokalemia
Address potassium-sparing diuretic use cautiously 6:
- With creatinine 1.7, potassium-sparing diuretics (spironolactone, amiloride) carry hyperkalemia risk
- Check potassium and creatinine 5-7 days after any adjustment 6
- If ACE inhibitor is continued (which it should be for ischemic heart disease), avoid routine potassium-sparing diuretics unless persistent hypokalemia occurs despite ACE inhibitor 6
Anemia Management
The normocytic anemia requires:
- Transfusion target hemoglobin >8 g/dL during acute bleeding
- Iron studies once bleeding controlled
- Avoid erythropoietin-stimulating agents acutely (increases thrombotic risk)
Left Renal Mass Consideration
The complex renal mass requires oncology evaluation but should not delay cardiovascular stabilization. Antiplatelet therapy decisions are based on cardiovascular risk, not the renal mass.
Lacunar Infarct and Gait Ataxia
The chronic lacunar infarct supports need for antiplatelet therapy long-term but does NOT change acute management. Once GI bleeding is controlled, aspirin monotherapy provides both cardiac and cerebrovascular protection.
Diabetes Management
Maintain glucose control but avoid hypoglycemia during acute illness. Metformin should be held temporarily given creatinine 1.7 and acute illness (lactic acidosis risk).
Monitoring Protocol
First 48 hours:
- Continuous telemetry for arrhythmia/ischemia
- Serial hemoglobin every 6 hours
- Daily creatinine and potassium
- ECG if any chest pain recurs
Post-discharge (if bleeding controlled):
- Repeat endoscopy in 4-6 weeks to confirm healing
- Consider P2Y12 inhibitor resumption only if: (1) complete ulcer healing confirmed, (2) high-dose PPI continued, (3) >1 month post-stent
- Cardiology follow-up in 2 weeks
Common Pitfalls to Avoid
Do not continue DAPT during active major bleeding - this causes either fatal bleeding or necessitates complete antiplatelet cessation leading to stent thrombosis 1
Do not delay endoscopy beyond 12 hours - every hour without antiplatelet coverage increases stent thrombosis risk 1
Do not restart DAPT immediately after endoscopy - aspirin monotherapy is safer and provides adequate protection in high bleeding risk patients 1
Do not use NSAIDs for any indication - catastrophic in this patient with renal impairment, GI bleeding, and cardiovascular disease 6, 7
Do not stop ACE inhibitors for creatinine 1.7 - continue unless creatinine rises >30% from baseline 5